What is the mechanism of action of this treatment?

The most common treatments for narcolepsy, such as sodium oxybate and its low-sodium variant XYWAV, work primarily by modulating neurotransmitter activity in the brain. Sodium oxybate, the sodium salt of gamma-hydroxybutyrate (GHB), enhances slow-wave sleep and reduces symptoms of excessive daytime sleepiness (EDS) and cataplexy by acting on gamma-aminobutyric acid (GABA) type B receptors. This modulation helps stabilize sleep architecture and improve overall sleep quality. The low-sodium formulation, XYWAV, offers similar benefits while reducing sodium intake, which can be particularly important for patients concerned about blood pressure and cardiovascular health. Effective management of these symptoms is crucial for improving the quality of life and daily functioning of narcolepsy patients.

What side effects are associated with this type of intervention?

Common treatments for narcolepsy, such as sodium oxybate, can cause side effects including nausea, dizziness, headache, and enuresis. High-sodium oxybate may increase blood pressure due to its sodium content. XYWAV, a low-sodium oxybate, aims to reduce sodium intake and potentially lower blood pressure. Other treatments like modafinil and pitolisant can cause headaches, nausea, and anxiety. Antidepressants used for cataplexy, such as venlafaxine and fluoxetine, may cause dry mouth, insomnia, and sexual dysfunction.

What prior FDA approvals exist?

The FDA has approved several treatments for narcolepsy, including sodium oxybate (Xyrem) and its low-sodium formulation, XYWAV. Sodium oxybate has been shown to be effective in reducing cataplexy attacks and excessive daytime sleepiness. XYWAV, a newer formulation with lower sodium content, aims to provide similar benefits while potentially reducing the risk of high blood pressure associated with high sodium intake. Other FDA-approved treatments for narcolepsy include modafinil and armodafinil, which are wake-promoting agents, and solriamfetol, which is used to improve wakefulness in adults with narcolepsy.

What other types of research exist?

Promising novel alternatives to XYWAV for narcolepsy patients in 2024 may include orexin receptor antagonists, which are being studied for their potential to regulate sleep-wake cycles. Additionally, advancements in cannabinoid-based therapies, such as dronabinol, are being investigated for their effects on sleep disorders and may offer new treatment options. Patients should discuss these emerging therapies with their healthcare providers to determine the best course of action.

← Back to Search

Sodium Oxybate

Low-Sodium Oxybate for Narcolepsy

Phase 4

Recruiting

Research Sponsored by Jazz Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, up to 6 weeks

Awards & highlights

Study Summary

This trial looks at how transitioning from a high-sodium oxybate to a low-sodium one affects blood pressure in narcolepsy patients, to provide info for HCPs, patients, and payers.

Who is the study for?

Adults aged 18-70 with narcolepsy, currently treated with high-sodium oxybate and stable doses of any blood pressure or wakefulness medications for at least 6 weeks prior to the study. Participants must not be pregnant, breastfeeding, have unstable medical conditions, significant cardiovascular disease, or psychiatric disorders that could impact their safety or study results.Check my eligibility

What is being tested?

The trial is testing the effect on blood pressure when switching from high-sodium oxybate (XYREM) to a low-sodium version called XYWAV in people with narcolepsy. The goal is to see if reducing sodium intake through medication changes can improve blood pressure.See study design

What are the potential side effects?

While specific side effects are not listed here, participants may experience changes related to lower sodium levels and adjustments in sleep patterns due to the switch from one medication (high-sodium oxybate) to another (low-sodium XYWAV).

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, up to 6 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, up to 6 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, up to 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change from baseline to End of Treatment (EOT) Visit on the 24-hour average Systolic Blood Pressure (SBP) in mmHg

Secondary outcome measures

Change from baseline to EOT Visit on the daytime average SBP in mmHg

Change from baseline to EOT Visit on the nighttime average SBP in mmHg

Change from baseline to EOT Visit on the seated resting average SBP in mmHg

Trial Design

1Treatment groups

Experimental Treatment

Group I: JZP258Experimental Treatment1 Intervention

Participants will receive 6 to 9 grams per night of JZP258 (XYWAV) for 6 consecutive weeks.

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for narcolepsy, such as sodium oxybate and its low-sodium variant XYWAV, work primarily by modulating neurotransmitter activity in the brain. Sodium oxybate, the sodium salt of gamma-hydroxybutyrate (GHB), enhances slow-wave sleep and reduces symptoms of excessive daytime sleepiness (EDS) and cataplexy by acting on gamma-aminobutyric acid (GABA) type B receptors. This modulation helps stabilize sleep architecture and improve overall sleep quality. The low-sodium formulation, XYWAV, offers similar benefits while reducing sodium intake, which can be particularly important for patients concerned about blood pressure and cardiovascular health. Effective management of these symptoms is crucial for improving the quality of life and daily functioning of narcolepsy patients.

Treatment paradigms for cataplexy in narcolepsy: past, present, and future.Recent advances in the treatment of narcolepsy.

Find a Location

Who is running the clinical trial?

Jazz PharmaceuticalsLead Sponsor

249 Previous Clinical Trials

34,814 Total Patients Enrolled

15 Trials studying Narcolepsy

3,995 Patients Enrolled for Narcolepsy

Media Library

High-Sodium Oxybate (Sodium Oxybate) Clinical Trial Eligibility Overview. Trial Name: NCT05869773 — Phase 4

Narcolepsy Research Study Groups: JZP258

Narcolepsy Clinical Trial 2023: High-Sodium Oxybate Highlights & Side Effects. Trial Name: NCT05869773 — Phase 4

High-Sodium Oxybate (Sodium Oxybate) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05869773 — Phase 4

~43 spots leftby Jun 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.